Sanofi (SNY) Liabilities and Shareholders Equity (2009 - 2026)

Sanofi has disclosed Liabilities and Shareholders Equity across 18 years of filings, most recently posting $149.9 billion for Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $149.9 billion, up 8.04% year-over-year; the trailing twelve-month figure through Mar 2026 was $590.7 billion (up 40.51% YoY), and the FY2025 annual result was $147.6 billion, up 4.02% from the prior year.
• Liabilities and Shareholders Equity came in at $149.9 billion for Q1 2026 at Sanofi, up from $147.6 billion in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $151.7 billion in Q3 2025 to a low of $129.3 billion in Q4 2022.
• The 5-year median for Liabilities and Shareholders Equity is $139.7 billion (2024), against an average of $140.3 billion.
• Across the five-year window, Liabilities and Shareholders Equity fell 6.01% in 2022 and climbed 8.04% in 2026, its largest moves.
• Sanofi's Liabilities and Shareholders Equity stood at $129.3 billion in 2022, then climbed by 5.24% to $136.1 billion in 2023, then climbed by 4.29% to $141.9 billion in 2024, then grew by 4.02% to $147.6 billion in 2025, then increased by 1.54% to $149.9 billion in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $149.9 billion (Q1 2026), $147.6 billion (Q4 2025), and $151.7 billion (Q3 2025), per Business Quant data.